{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:33:55Z","timestamp":1782124435322,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T00:00:00Z","timestamp":1181952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pemphigus vulgaris (PV) at the early, usually oral and relatively stable stage, represents the majority of PV patients. Treatment modalities usually do not differ compared to those for the fully established disease.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To prospectively assess a standardized and effective therapeutic approach that aims at less morbidity due to adverse reactions.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The following regimen, also known as Lever's mini treatment (LMT), was used. Forty mg of oral prednisone on alternate days plus 100\u00a0mg azathioprine every day were administered until the complete healing of all lesions. A gradual monthly and later bimonthly decrease of prednisone was followed by the tapering of a second immunosuppressive agent, in a one\u2010year period.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Seventy\u2010four patients suffering from early\u2010stage\u2010PV, and representing 70% of all PV patients seen through the years 1991\u20132003, were eligible in the study. Total follow\u2010up period was 76\u00a0\u00b1\u00a037 (26\u2013180) months. During the 53\u00a0\u00b1\u00a026 months of LMT, 6 (8%) patients dropped out of therapy, 9 (12%) required a change to another treatment, two (3%) died and 57 (77%) achieved a lesion\u2010free condition. Forty\u2010five (61%) patients were in complete remission for 27\u00a0\u00b1\u00a029 months. Significant morbidity was estimated 4\/74 (5.2%). Disease \u2018breakthroughs\u2019 necessitating treatment adjustments occurred in 30 patients, usually throughout the last phase of therapy and post\u2010treatment follow\u2010up.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> LMT may be a standardized therapeutic approach for the early and relatively stable stage of PV, resulting in high efficacy, safety and quality of life profile.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2007.02286.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T13:33:19Z","timestamp":1182000799000},"page":"1386-1391","source":"Crossref","is-referenced-by-count":14,"title":["An alternate\u2010day corticosteroid regimen for pemphigus vulgaris. A 13\u2010year prospective study"],"prefix":"10.1111","volume":"21","author":[{"given":"G","family":"Ch Chaidemenos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Mourellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Koussidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Tsatsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,16]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02612.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890260105016"},{"key":"e_1_2_5_4_2","first-page":"413","article-title":"Mucous membrane manifestations of pemphigus vulgaris. A 25\u2010year survey 0f 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin","volume":"68","author":"Mashkilleyson N","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1990.tb04765.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46652001000100007"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02738-5"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640090084013"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1984.01650370050009"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02497.x"},{"key":"e_1_2_5_11_2","first-page":"13","article-title":"Traitement du pemphigus vulgaire par le protocole \u2018Lever faible\u2019","volume":"130","author":"Benoit Corven C","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_5_12_2","first-page":"649","article-title":"Etude en peau saine de l\u2019immunofluorescence directe dans le pemphigus vulgaire","volume":"105","author":"Kanitakis C","year":"1978","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb04450.x"},{"key":"e_1_2_5_14_2","first-page":"465","article-title":"Factors promoting a successful and cost\u2010effective management of pemphigus vulgaris with high\u2010dose I.V. IgG","volume":"13","author":"Chaidemenos G","year":"2006","journal-title":"Int J Immunopathol Pharmacol, Section Dermatol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23930.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70069-3"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.059"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70018-2"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02218.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196802222780801"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.013"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05665.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)80380-1"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01266.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2007.02286.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2007.02286.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:26:59Z","timestamp":1696984019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2007.02286.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,16]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1468-3083.2007.02286.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02286.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,16]]}}}